Guest Column | November 18, 2026

Why Immunotherapy Has Had Limited Success In Epithelial Ovarian Cancer

By Robert W. Holloway, MD, DHc, FACOG, FACS

Femal reproductive system-GettyImages-2232154794

Many recent technological breakthroughs in cancer treatment have improved patient outcomes, but the benefits vary significantly across specific types of cancer. Despite therapeutic advances that have extended median overall survival (OS) for patients with advanced epithelial ovarian cancer (EOC), mortality from EOC has only marginally improved. Immune checkpoint inhibition (CPI) has been extraordinarily impactful for disease control and survival in cervical and certain types of endometrial cancers, yet the impact for EOC has been modest at best. Increasingly, we have come to understand why immunotherapy has underperformed for ovarian cancer either as a single-agent therapy1 or in combination with other agents.2–4

Ovarian Cancer’s Hard, “Cold” Truth

Disappointing results from immunotherapy trials in ovarian cancer stem primarily from two factors: low immunogenicity and a profoundly immunosuppressive tumor microenvironment (TME). In immunological terms, solid tumors are on an immunologic spectrum from inherently immunologically “cold” to varying degrees of being immunologically “hot.”  A hot tumor is loosely defined as one that triggers a significant immune response, evidenced by the presence of tumor-infiltrating lymphocytes (TILs), rather than merely lymphocytes around the tumor. Immunologists and pathologists evaluate a tumor’s immunogenicity by how many and how deeply TILs have infiltrated. A cold tumor shows little or no infiltration of TILs, indicating that the patient’s native immune system has not recognized the tumor as foreign. Hot tumors, such as melanoma and bladder cancer, respond better to immunotherapy, compared with cold tumors, such as pancreatic cancer and glioblastoma.5

The most common type of EOC, high-grade serous ovarian cancer (HGSOC), is generally an immunologically “cold” tumor with a low-to-intermediate mutational burden, few neoantigens, and abundant suppressive cellular and molecular local micro-immune characteristics that prevent effective CPI activity.1,6–7 Consequently, single-agent anti–PD-1 (programmed cell death protein 1) / PD-L1 (programmed death-ligand 1) agents yield objective response rates (ORR) of only 5% to 15%, and nearly every randomized trial of CPIs as monotherapy or in combination with chemotherapy or antiangiogenics has failed to improve survival.8

Even though approximately 55% of ovarian cancers have T-cell infiltration,9 the TME is dominated by regulatory T cells, M2 macrophages, and myeloid-derived suppressor cells that collectively impair T-cell trafficking and many other immunosuppressive mechanisms.10 While the response rate with checkpoint inhibition in advanced/recurrent ovarian cancer is modest, some patients do benefit in terms of disease response and survival.

A Pipeline Of Advanced Therapies Turning Cold Tumors Immunologically Hot

“Stealthy” is an adjective often applied to ovarian cancer. Its early symptoms are often vague, allowing it to go undetected, and after chemotherapy makes some initial gains, ovarian cancer usually evades therapy and recurs. This characteristic of EOC presents one of the greatest challenges in gynecologic oncology, and it is part of a larger landscape of activity in developing immunotherapy for solid tumors. The fight to improve the outlook for patients with EOC is happening on many fronts.

Investigational immunotherapy in ovarian cancer spans six broad strategies, unified by the goal of converting immunologically “cold” tumors into “hot,” T-cell-inflamed ones:

  • next-generation and combination checkpoint blockade
  • adoptive cell therapy
  • therapeutic cancer vaccines
  • bispecific antibodies and T-cell engagers
  • oncolytic virotherapy
  • TME-reprogramming and myeloid/innate-targeting approaches.

In-depth review of these investigational therapies is beyond the scope of this article. However, our institutional clinical research program has trials investigating bispecific antibodies that bring activated T cells into contact with the cancer cells, targeting antibodies that deliver cytotoxic therapy directly to the cancer cell, and oncolytic virus therapy that modulates the immune microenvironment to enhance subsequent platinum-based treatment. In addition, we are actively building a solid-tumor cellular therapy program with our hematology-oncology colleagues and will initiate trials in stimulated cellular therapy in the coming year.

I currently serve as national principal investigator on Genelux’s 31-site Phase 3 OnPrime trial evaluating olvimulogene nanivacirepvec (Olvi-Vec), a genetically modified oncolytic vaccinia virus for platinum-resistant/refractory ovarian cancer.11 Vaccinia virus is not a natural human pathogen. Olvi-Vec has been designed with a defective viral thymidine kinase gene, making it dependent on an abundant nucleotide pool to replicate. Consequently, it is preferentially active in rapidly reproducing cancer cells, which have high thymidine levels, but not in the adjacent stromal tissue or ovarian cortex.

Inside thymidine-rich cancer cells, the virus proliferates, induces lysis of the cellular membrane, and infects adjacent cells while releasing tumor-specific proteins (oncoproteins) to stimulate the immune system. As the oncoproteins activate the immune system, T cells multiply and kill the cancer cells that express these proteins. In the ongoing OnPrime clinical trial, patients receive two treatments of Olvi-Vec via abdominal catheter, and viral replication in the abdominal cavity continues until the patient’s immune response ends the viral life cycle.

The oncolytic virus primes the immune system; when that’s followed by platinum doublet therapy, a 54% ORR was reported in heavily pretreated patients in the Phase 2 study.12 Median progression-free survival was 11.0 months, and median OS was 15.7 months (14.7 in platinum-refractory vs. 18.5 in platinum-resistant).12 The multi-institutional Phase 3 OnPrime registrational study is ongoing.

Changing The Future Of Front-Line Therapies

Many cancer treatments are now in development for targeting later stages of the disease. While treatments have potential to improve the prognosis for these patients with platinum-resistant/refractory disease, more research is needed to explore the potential of immune-activated treatments earlier in the disease process rather than waiting until patients are treatment resistant with symptomatic disease. Hopefully, future clinical trials incorporating circulating tumor DNA (ctDNA) monitoring can be designed to predict recurrence and initiate novel therapies earlier in the disease course.13 Given the complexity of the immune response to malignancy, there will likely not be one breakthrough immunotherapy in ovarian cancer, and improving cure rates will require several of these novel interventions in sequence or combination.  Our team remains committed to being on the front line of clinical trials that may improve outcomes for our patients with EOC. Considering the pace of biomedical discovery in the recent past, we remain optimistic that immunotherapy will find a more effective role in therapy for EOC.

References

  1. Matulonis, U. A., Shapira-Frommer, R., Santin, A. D., et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7): 1080–1087. doi:10.1093/annonc/mdz135
  2. Monk BJ, Colombo N, Oza AM, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (9): 1275-1289. doi:10.1016/S1470-2045(21)00342-9
  3. Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034-1046. doi:10.1016/S1470-2045(21)00216-3
  4. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019; 5 (8): 1141-1149. doi:10.1001/jamaoncol.2019.1048
  5. Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018; 6(1): 157. doi:10.1186/s40425-018-0479-7
  6. Zamarin D, Burger RA, Sill MW, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG Oncology Study. J Clin Oncol. 2020; 38 (16):1814-1823. doi:10.1200/JCO.19.02059
  7. Peng Z, Li H, Gao Y, et al. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(10):1288-1297. doi:10.1016/S1470-2045(24)00437-6
  8. Marchetti C, Sassu CM, Cefaliello A, et al. First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression. Crit Rev Oncol Hematol. 2026;224:105383. doi:10.1016/j.critrevonc.2026.105383
  9. Vida R, Bartoletti M, Montico M, et al. Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials. Cancer Treat Rev. 2026;144:103094. doi:10.1016/j.ctrv.2026.103094
  10. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348:203-13. doi:10.1056/NEJMoa020177
  11. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT05281471
  12. Holloway RW, Mendivil AA, Kendrick JE, et al. Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: The nonrandomized phase 2 VIRO-15 clinical trial. JAMA Oncol. 2023; 9 (7): 903-908. doi:10.1001/jamaoncol.2023.1007
  13. Blakey-Cheung S, Dwivedi B, Rivero-Hinojosa S, et al. Post-treatment ctDNA monitoring using a tumor-informed whole-genome sequencing-based assay in homologous recombination–proficient ovarian cancer. Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 - June 2, 2026, Chicago, IL [J Clin Oncol. 2026; 44 (16 Suppl.): 5592]. doi:10.1200/JCO.2026.44.16_suppl.5592

Disclosures: Dr. Robert Holloway is a member of the Genelux Clinical Advisory Board.

About The Author

Robert W. Holloway, MD, DHc, FACOG, FACS, is medical director of gynecologic oncology at AdventHealth Cancer Institute, Orlando, Florida.